Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Fixed duration ibrutinib plus venetoclax,previously untreated chronic lymphocytic leaukaemia (CLL) with TP53 mutation,Fixed duration ibrutinib plus venetoclax,Only if cost neutral or cost saving,,
